"Our data would suggest that if Worldwide Clinical Trials is not on your radar as a potential CRO partner, you should consider some due diligence on them as they were the only CRO with a strong "preference profile" that also had a favorable price perception." Source: ISR 2012 CRO Quality Benchmarking Report
The comprehensive report provides performance scorecards on 25 CROs, based on the interviews of 125 industry professionals, spanning 72 pharmaceutical and biotechnology companies. CROs were assessed across 21 service characteristics determined to be influential in provider selection, loyalty and operational performance. Key highlights of Worldwide Clinical Trials (WCT) performance include:
Angelico Carta, M.D., President, Worldwide Clinical Trials’, provided thoughtful comment on the report and how its findings support the company’s business philosophy:
"We are very proud of WCT’s performance in this major market research study. We pride ourselves on our operational intelligence and clearly, as the report underscores, our clients are recognizing WCT for the very attributes needed to develop and run clinical trials successfully."
He continued:
"The data around Service Provider Loyalty is remarkable. WCT has long been known for being loyal to our clients and it is fulfilling to learn that our clients are equally loyal and supportive of WCT. Our data would suggest that if Worldwide Clinical Trials is not on your radar as a potential CRO partner, you should consider some due diligence on them as they were the only CRO with a strong "preference profile" that also had a favorable price perception."
"Knowing that a client will continue to use WCT, is satisfied and would recommend us, speaks to what we value most; and what we value most is client satisfaction."